Performance d’engraissement de poulets mâles nourris avec différentes sources de protéines

Les performances de croissance de mâles d’hybrides de ponte recevant une alimentation comportant des sources et des teneurs différentes en protéines ont été étudiées dans trois essais d’engraissement. Par rapport aux hybrides d’engraissement Hubbard JA 757 (HUB), les poulets mâles des génotypes Lohmann Braun (LB) et Lohmann Selected Leghorn (LSL) présentent une moins bonne performance d’engraissement. Le poids vif, la prise de poids journalière et le poids à l’abattage sont influencés par le génotype. Les mâles LB présentent cependant de nets avantages en termes de performance par rapport aux mâles LSL. Le remplacement partiel du soja par de la farine de luzerne verte dans les rations, qui s’accompagne d’une réduction de l’apport en protéines, entraîne une perte de rendement, en particulier pour la lignée HUB. À l’inverse, le passage à des rations à plus faible teneur en protéines s’est avéré avantageux pour le génotype LB, ce qui offre la possibilité pour l’engraissement de poulets mâles de compenser, par la composition de la ration, la moindre efficacité alimentaire des mâles

Mastleistung von Bruderhähnen bei Fütterung mit unterschiedlichen Proteinquellen

In drei Mastversuchen wurden die Wachstumsleistungen männlicher Legehybriden bei Fütterung mit unterschiedlichen Proteinquellen und -gehalten untersucht. Der Vergleich der Genotypen Lohmann Braun (LB) und Lohmann Selected Leghorn (LSL) mit dem Masthybriden Hubbard JA 757 (HUB) zeigte, dass die Bruderhähne erwartungsgemäss geringere Mastleistungen aufwiesen. Sowohl die Lebendgewichte und täglichen Zunahmen als auch die Schlachtgewichte wurden vom Genotyp beeinflusst. Die LB-Hähne wiesen jedoch deutliche Vorteile in den Leistungen gegenüber den LSL-Tieren auf. Der partielle Ersatz von Soja durch Luzernegrünmehl in den Rationen, der mit einer Proteinreduktion einhergeht, führte vor allem bei HUB zu Leistungseinbussen. Im Gegensatz dazu konnten für den Genotyp LB Vorteile in der Umsetzung von Rationen mit reduziertem Proteingehalt festgestellt werden, was für die Mast der Bruderhähne die Möglichkeit bietet, mit der Rationsgestaltung der niedrigen Effizienz der Tiere entgegenzuwirken

Left ventricular ejection fraction and cardiac biomarkers for dynamic prediction of cardiotoxicity in early breast cancer

BACKGROUND/PURPOSE: This study aims to quantify the utility of monitoring LVEF, hs-cTnT, and NT-proBNP for dynamic cardiotoxicity risk assessment in women with HER2+ early breast cancer undergoing neoadjuvant/adjuvant trastuzumab-based therapy. MATERIALS AND METHODS: We used joint models of longitudinal and time-to-event data to analyze 1,136 echocardiography reports and 326 hs-cTnT and NT-proBNP measurements from 185 women. Cardiotoxicity was defined as a 10% decline in LVEF below 50% and/or clinically overt heart failure. RESULTS: Median pre-treatment LVEF was 64%, and 19 patients (10%) experienced cardiotoxicity (asymptomatic n = 12, during treatment n = 19). The pre-treatment LVEF strongly predicted for cardiotoxicity (subdistribution hazard ratio per 5% increase in pre-treatment LVEF = 0.68, 95%CI: 0.48–0.95, p = 0.026). In contrast, pre-treatment hs-cTnT and NT-proBNP were not consistently associated with cardiotoxicity. During treatment, the longitudinal LVEF trajectory dynamically identified women at high risk of developing cardiotoxicity (hazard ratio per 5% LVEF increase at any time of follow-up = 0.36, 95% CI: 0.2–0.65, p = 0.005). Thirty-four patients (18%) developed an LVEF decline ≥ 5% from pre-treatment to first follow-up (“early LVEF decline”). One-year cardiotoxicity risk was 6.8% in those without early LVEF decline and pre-treatment LVEF ≥ 60% (n = 117), 15.9% in those with early LVEF decline or pre-treatment LVEF 5% during trastuzumab-based therapy. The longitudinal LVEF trajectory but not hs-cTnT or NT-proBNP allows for a dynamic assessment of cardiotoxicity risk in this setting

Design Management Program Application for Internet Access in STMIK Jakarta Pusyanet

A medium used for the general course requires management to continuity ofoperations, not much different from the means of Internet access that is intended forstudents STMIK Jakarta. By using application programs created with Visual Basiclanguage, management of user identities, the use and timing of each user requests alist of all of them are stored in the database using Microsoft Access

MiR-200c-3p modulates cisplatin resistance in biliary tract cancer by ZEB1-independent mechanisms

Biliary tract cancer is a major global health issue in cancer-related mortality. Therapeutic options are limited, and cisplatin-based treatment schedules represent the mainstay of first-line therapeutic strategies. Although the gain of survival by the addition of cisplatin to gemcitabine is moderate, acquired cisplatin resistance frequently leads to treatment failures with mechanisms that are still poorly understood. Epithelial–mesenchymal transition (EMT) is a dynamic process that changes the shape, function, and gene expression pattern of biliary tract cancer cells. In this study, we explored the influence of the EMT-regulating miR-200c-3p on cisplatin sensitivity in biliary tract cancer cells. Using gain of function experiments, we demonstrated that miR-200c-3p regulates epithelial cell markers through the downregulation of the transcription factor ZEB1. MiR-200c-3p upregulation led to a decreased sensitivity against cisplatin, as observed in transient overexpression models as well as in cell lines stably overexpressing miR-200c-3p. The underlying mechanism seems to be independent of miR-200c-3p’s influence on ZEB1 expression, as ZEB1 knockdown resulted in the opposite effect on cisplatin resistance, which was abolished when ZEB1 knockdown and miR-200c-3p overexpression occurred in parallel. Using a gene panel of 40 genes that were previously associated with cisplatin resistance, two (Dual Specificity Phosphatase 16 (DUSP16) and Stratifin (SFN)) were identified as significantly (>2 fold, p-value < 0.05) up-regulated in miR-200c-3p overexpressing cells. In conclusion, miR-200c-3p might be an important contributor to cisplatin resistance in biliary tract cancer, independently of its interaction with ZEB1